[Market Moves Interpretation] Sana Biotechnology soars on September 17: Clinical Advancements + Diabetes + CAR-T

1. On September 14, the company introduced its gene editing and stem cell-derived islet therapy at the Morgan Stanley Global Healthcare Conference. It expects to obtain IND approval and launch Phase I trials this year, with in vivo CAR-T platform clinical data anticipated for release in 2027.
2. On September 15, the company disclosed that its low-immunity cell therapy for type 1 diabetes is planned to submit an IND and launch Phase I/II trials by the end of the year. First-in-human data for the SG293 in vivo CAR-T therapy is expected within the next 12 months. The company primarily focuses on engineered cell medicines, advancing clinical preparations for SC451 and SG293.

(Disclaimer: This content is summarized from publicly available information gathered by AI technology and is for reference only; it does not constitute investment advice.)